QED has been awarded a multinational Phase II clinical trial with polyclonal antibodies in patients with Idiopathic Thrombocytopenic Purpura (ITP).
ITP is an autoimmune bleeding disorder characterized by abnormally low platelet levels, making it difficult for the blood to clot normally. It is a chronic and debilitating disease, associated with increased bleeding risk and impaired quality of life.
Thomas Ogorka, QED’s CEO said “We are very pleased to assist the Sponsor with this challenging study in a rare disease such as ITP. The success of this study will be directly linked with the selection of high quality Investigators and of course our experienced study team”.